Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial
Eli M. Roth (Lead / Corresponding author), Marja-Riitta Taskinen, Henry N. Ginsberg, John J. P. Kastelein, Helen M. Colhoun, Jennifer G. Robinson, Laurence Merlet, Robert Pordy, Marie T. Baccara-Dinet
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial'. Together they form a unique fingerprint.